OpenAI's Rosalind Academic Plan gives US research labs 30 free seats for a year

OpenAI on October 15 introduced the Rosalind Academic Plan, a sponsored program that gives eligible US academic labs up to 30 Business Standard seats at $0 per user per month for as long as 12 months. The headline asset is GPT-Rosalind, OpenAI's dedicated life sciences model, which labs receive through a trusted-access approval process. The Decoder independently confirms the eligibility rules, the 30-seat cap, the one-year duration and the API exclusion.

What labs actually get

Each approved lab receives up to 30 named seats. The plan bundles access to all commercially available frontier OpenAI models, subject to standard plan usage limits, so a lab is not locked to a single specialized model. GPT-Rosalind itself unlocks only after trusted-access approval. OpenAI also states that research data shared through the plan is not used to train its models by default.

GPT-Rosalind is positioned for deeper reasoning on complex biological questions. It pairs with the Rosalind Workbench, which orchestrates specialized tools across medicinal chemistry, genomics and wet-lab assistance. The named use areas run from drug and protein design and liquid-biopsy diagnostics to vaccines, RNA therapeutics, agriculture, ecology and antimicrobial resistance.

Who qualifies, and how to apply

The plan is currently limited to academic labs at US universities. Two paths exist. PIs and lab leads at universities without an OpenAI Enterprise agreement apply directly through the trusted-access process. Labs at universities that already have an Enterprise agreement must request GPT-Rosalind access through their institution's existing Enterprise channel instead.

Once approved, the PI or lab lead activates access for up to 30 named members, manages their permissions and carries responsibility for the lab's approved use. Application requires describing the research, completing verification and signing an agreement. API access is not included at this time.

Safety vetting is part of the product

OpenAI verifies the institution's legitimacy and the lab lead's identity, background and authority before activation. It reviews the lab's affiliation, research activities and intended use, and requires a designated institutional safety contact. Monitoring continues after activation; for registered high-sensitivity use cases, safety checks account for the approved research context, and OpenAI says it may follow up with researchers to confirm authorization when something is unclear.

That design reflects the model's subject matter: the same reasoning that assists drug design also touches dual-use biological questions. Early examples cited on OpenAI's page include the Zhao Lab at UCSF, which used the model to gather drug physicochemical parameters across ten drugs, plus work on protein design and neurodegeneration at Stanford and the Arc Institute.

What this changes for research labs

A free year of 30 Business seats is a material entitlement shift for a defined audience: US academic life-science groups that could previously only reach this tier through paid plans or institution-wide Enterprise deals. For labs already under an Enterprise agreement, the practical step is asking their admin to route a GPT-Rosalind access request rather than filing a new application. Non-US labs still have no path through this plan, and teams that need programmatic workflows should note that API access is explicitly excluded for now.

LinkLoot's read: the vetting gate matters as much as the free seats. Expect slower onboarding than a ordinary plan signup, and budget time for verification and the safety-contact designation before the lab can actually work.

Related: AI agent tools guide.

Sources

• OpenAI: Bringing GPT-Rosalind to academic research labs (primary, official)
• The Decoder: OpenAI's new Rosalind Academic Plan gives research labs up to 30 free seats for a year (independent corroboration)